TABLE 3.
Relapses of AAV in patients with KTX
| No | Disease | ANCA type (C/P) | Age at KTX | Gender | KTX type | Preemptive (Y/N) | Remission >12 mo at KTX (Y/N) | ANCA status at KTX (±/NK) | Follow-up post KTX (mo) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WG | C | 30 | F | DD | N | N | + | 88 |
| 2 | WG | C | 20 | F | LRD | N | N | − | 165 |
| 3 | WG | NK | 34 | F | LURD | N | Y | NK | 48 |
| 4 | WG | C | 65 | M | LRD | N | Y | + | 74 |
| 5 | WG | C | 39 | M | LRD | N | Y | + | 59 |
| 6 | MPA | P | 47 | M | LRD | N | Y | NK | 81 |
| 7 | MPA | P | 69 | F | DD | N | Y | + | 118 |
DD, deceased donor; F, female; M, male; KTX, kidney transplant; LRD, living related donor; LURD, living unrelated donor; N, no; Y, Yes; NK, not known; WG, Wegener’s granulomatosis; MPA, microscopic polyangiitis; ANCA, antineutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis.